Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Outline of Final Research Achievements |
Among several innate immune signaling molecules, MyD88 in donor T cells were critical for the maximization of graft versus host disease (GVHD) after murine allogeneic bone marrow transplantation. T cells lack of single upstream molecules of MyD88 caused equivalent GVHD compared to wild type T cells, indicating that an overall blockade of MyD88-dependent signals in T cells are required for GVHD amelioration. MyD88 deficient T cells showed severely impaired Th1 response compared to wild type T cells upon CD3/CD28 stimulation and allogeneic stimulation. MyD88 deficient donor T cells exerted significant graft versus leukemia effects, suggesting that MyD88 inhibitor is a promising therapeutic reagent against GVHD in clinical transplantation.
|